Chenodal
Total Payments
$1.7M
Transactions
333
Doctors
8
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $568,362 | 24 | 5 |
| 2023 | $493,684 | 77 | 4 |
| 2022 | $374,011 | 88 | 4 |
| 2021 | $246,958 | 144 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.6M | 308 | 95.8% |
| Consulting Fee | $46,865 | 18 | 2.8% |
| Grant | $23,000 | 1 | 1.4% |
| Travel and Lodging | $1,043 | 2 | 0.1% |
| Food and Beverage | $297.44 | 4 | 0.0% |
Payments by Type
Research
$1.6M
308 transactions
General
$71,205
25 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS (RESTORE) | Mirum Pharmaceuticals, Inc. | $566,494 | 0 |
| A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS | Travere Therapeutics, Inc. | $449,097 | 0 |
| A Phase 3 Study to Evaluate the Effects of Chenodeoxycholic Acid in Adult and Pediatric Patients With Cerebrotendinous Xanthomatosis | Travere Therapeutics, Inc. | $365,808 | 0 |
| CTX Prevalence: CTX Observational study in patients with early onset bilateral cateracts | Travere Therapeutics, Inc. | $172,155 | 0 |
| 018CTXX15001 (PREVALENCE) | Travere Therapeutics, Inc. | $41,797 | 0 |
| Cheno-CTX-301 (RESTORE) | Travere Therapeutics, Inc. | $10,350 | 0 |
| 021FSGS16010 | Travere Therapeutics, Inc. | $4,743 | 0 |
| CTX Prevalence: CTX Observational study in patients with early onset bilateral cateracts | Lantheus Medical Imaging, Inc. | $1,365 | 0 |
Top Doctors Receiving Payments for Chenodal
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Little Rock, AR | $1.6M | 309 |
| , MD | Clinical Biochemical Genetics | Marshfield, WI | $17,218 | 7 |
| , M.D | Endocrinology, Diabetes & Metabolism | Boston, MA | $16,546 | 5 |
| , MD | Clinical Cardiac Electrophysiology | Wynnewood, PA | $5,325 | 2 |
| , M.D | Neurodevelopmental Disabilities | Baltimore, MD | $4,650 | 4 |
| , MD | Neurology | Portland, OR | $2,400 | 3 |
| , M.D | Ophthalmology | Durham, NC | $2,000 | 1 |
| , MD | Neurology | Cleveland, OH | $32.94 | 1 |
| Erin Stehman | Family | Sheffield Village, OH | $32.94 | 1 |
Ad
Manufacturing Companies
- Travere Therapeutics, Inc. $1.1M
- Mirum Pharmaceuticals, Inc. $585,132
- Lantheus Medical Imaging, Inc. $1,365
Product Information
- Type Drug
- Total Payments $1.7M
- Total Doctors 8
- Transactions 333
About Chenodal
Chenodal is a drug associated with $1.7M in payments to 8 healthcare providers, recorded across 333 transactions in the CMS Open Payments database. The primary manufacturer is Travere Therapeutics, Inc..
Payment data is available from 2021 to 2024. In 2024, $568,362 was paid across 24 transactions to 5 doctors.
The most common payment nature for Chenodal is "Unspecified" ($1.6M, 95.8% of total).
Chenodal is associated with 8 research studies, including "A PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS (RESTORE)" ($566,494).